Applying for GP2 Data Access on the AMP® PD Platform
Back to Blog Feed

Applying for GP2 Data Access on the AMP® PD Platform

By Justin C. Solle, Claire Wegel, Eline Appelmans, and Kaileigh Murphy | Research Collaboration, Research Operations |
Author(s)
  • Justin Solle

    Justin C. Solle, MBA

    Michael J. Fox Foundation | USA

    Justin joined The Michael J. Fox Foundation for Parkinson’s Research in 2021 as Senior Associate Director. He focuses on leading the Global Parkinson’s Genetics Program and also supports operations and recruitment for the Parkinson’s Progression Markers Initiative. Email: [email protected]

  • Claire Wegel, MPH

    Indiana University School of Medicine | USA

    Claire received her MPH in Epidemiology from the University of Minnesota in 2006. Claire is the project manager for several biorepositories housed at Indiana University; in that capacity, she leads biorepository operations including sample collection and reconciliation, training study staff, and biospecimen sharing efforts. Email: [email protected]

  • Eline Appelmans

    Foundation for the National Institutes of Health | USA

    As Director of Neuroscience Research Partnerships, Dr. Appelmans works in coordination with the NIH, non-profit, industry leaders, and FNIH project leads on the teams’ implementation of AMP®, AMP-AD, AMP PD, AMP for Schizophrenia (AMP-SCZ), the Alzheimer’s Disease Neuroimaging Initiative 3 Private Partner Scientific Board (ADNI3 PPSB) and the Biomarkers Consortium Neuroscience Steering Committee (BC NSC). Email: [email protected]

  • Kaileigh Murphy

    Michael J. Fox Foundation | USA

    Kaileigh joined the Michael J. Fox Foundation in 2019. As a project manager, Kaileigh manages a diverse grant portfolio. In addition to managing grants, she also works on various special projects related to our research grants, mainly within the Global Parkinson’s Genetics Program and the Aligning Science Across Parkinson’s initiative. Email: [email protected]  

Earlier this year, the Global Parkinson’s Genetics Program (GP2) collaborated with the Accelerating Medicines Partnership® Program: Parkinson’s Disease (AMP PD) to provide Parkinson’s disease (PD) genetic data for research of novel drug targets and biomarkers, as well as collaborative cloud-based computing. The AMP PD cloud platform will provide a single, secure access point for data collated and generated by GP2. While GP2 values open science and access, we are prioritizing the safety and security of data through verified researcher authentication in a process which we are excited to share.

Access Request Form and Google Account:

Applying for GP2 data access begins when an investigator applies for access to the AMP PD portal using the Registration Form. Access to data requires a Google Account, whether it be an institutional account, a Google account associated with your institutional email address, or a Gmail account.

Tiered Access:

There are currently two tiers of data access through AMP PD. Users in Tier 1 can access limited individual-level clinical data, omics summary results, and/or related metadata. Tier 2 allows users access to the full GP2 dataset, with individual-level clinical and genetics data, as well as metadata.

Data Use Agreement:

Once users complete an online registration form and verify their email address, they will be asked to electronically sign a Data Use Agreement (DUA) for access to Tier 1-level data. To access Tier 2 data, users must submit a DUA which includes a signature from the user’s Authorized Institutional Signatory (on behalf of the institution under which they will conduct their research) in a PDF format that can be submitted to the GP2 Access Compliance Team via email or attached to the application.

Cohort Objection Period:

In order to promote data fairness and equity, and to ensure GP2 follows all local laws and regulations, all GP2 Cohort Contributors (Principal Investigators) who have contributed data and/or DNA samples to GP2 will receive email notice of all Tier 2 data use requests through AMP-PD. When the institutionally signed DUA is submitted, GP2 Contributors will receive an automated email with the name, institution, and proposed analyses of the investigator who has requested data access. GP2 Contributors will have 120 hours to submit an objection to the data access request, based on history of data misuse, research misconduct or a proposed data use that violates the limits of the consent of participants in the study contributed to GP2. If there are no objections after 120 hours, the data use access request will be approved. If an objection is raised, GP2 leadership will evaluate the objection and come to a resolution.

Data security is of the highest importance to GP2 and AMP PD. Please contact the Operations and Compliance Working Group at [email protected] if you have questions or suggestions about the AMP PD data access process.